{"schema_version":"secwatch.filing_event.v1","accession":"0001581280-26-000016","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.525145+00:00","generated_at":"2026-05-16T05:36:17.687458+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M","bullets":["Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.","Gross margin 52.0% (+4 pts YoY); net loss narrowed to $30.5M ($0.50/share) vs $31.6M.","DNA Synthesis & Protein Solutions rev $51.1M (+27% YoY); NGS Apps $52.6M (+8%, ex-large customer +18%).","FY2026 revenue guidance raised to $435-440M; reaffirms Q4 Adj EBITDA breakeven on track.","Cash $198M; shipped to ~2,538 customers, ~271,000 genes; launched research-grade plasmid DNA preps."],"urls":{"canonical":"https://secwatch.observer/filing/0001581280-26-000016","json":"https://secwatch.observer/filing/0001581280-26-000016.json","markdown":"https://secwatch.observer/filing/0001581280-26-000016.md","text":"https://secwatch.observer/filing/0001581280-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000016/0001581280-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000016/twist-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:36:17.687458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}